← Leaderboards
Andrea Cuconati
Pharmabridge, Inc.
$3,869,294
Attributed
$5,218,439
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2008–14$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$5,218,439 · 5
By mechanism
R01$2,055,248 · 1
R44$1,980,003 · 1
R56$643,042 · 1
R43$540,146 · 2
Top collaborators
- Haitao Guo6 shared
Others in their field
Top investigators on “High Throughput Screening”
- Richard A Gibbs · Baylor College Of Medicine$250,166,309
- Leonard Freedman · Leidos Biomedical Research, Inc.$249,633,249
- David Heimbrook · Leidos Biomedical Research, Inc.$181,270,700
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,111,713
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
Research focus
High Throughput ScreeningInfectionChronicHepatitis B VirusViralAnti-Hepatitis BResponseBasePharmaceutical PreparationsWoodchuckTissue CultureHousingSeriesPolymeraseIn VivoHepatitis BLeadVirusDrug KineticsAntiviral AgentsInhibitor/AntagonistCellsDrug ResistanceIn Vitro
Grant awards (10)
Development of a novel drug candidate that inhibits hepatitis B virus covalently$1
R01 · FY2014 · AI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$603,728
R01 · FY2013 · AI
Discovery of Anti-HBV cccDNA Compounds from a Unique Natural Products Collection$300,000
R43 · FY2013 · AI · contact PI
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection$980,003
R44 · FY2012 · AI · contact PI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$627,419
R01 · FY2012 · AI
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection$1,000,000
R44 · FY2011 · AI · contact PI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$824,100
R01 · FY2011 · AI
Screen for an unexploited step in the HBV life cycle$305,542
R56 · FY2009 · AI · contact PI
Screen for an unexploited step in the HBV life cycle$337,500
R56 · FY2008 · AI · contact PI
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection$240,146
R43 · FY2008 · AI · contact PI